Enlivex Therapeutics Ltd.
ENLV · NASDAQ
Market closed$4.68$-0.070000 (-1.47%)After hours $4.68 · 0.00%
Key statistics
Previous close$4.75
Open$4.50
Day high$4.99
Day low$4.50
52-week high$31.50
52-week low$4.32
Market cap78.77M
Volume118.15K
Average volume36.57K
P/E ratio0.01
Forward P/E—
EPS404.50
Dividend yield0.00%
Market context
Why it moved
ENLV shares declined modestly alongside a broad market sell-off driven by a deepening AI stock rout, with the S&P 500 and Nasdaq falling sharply as concerns mounted over stretched valuations in the tech sector.
What is happening
Recent company-specific developments and publisher coverage.
Investing.com Nigeria · July 13, 2026FDA grants regenerative medicine designation to Enlivex therapy By Investing.comStock Titan · July 13, 2026FDA flags Enlivex’s Allocetra as potential new option for painful knee osteoarthritisStock Titan · June 24, 2026Enlivex token gets Gate listing, widening access to its $1.14B treasury assetStock Titan · June 2, 2026Enlivex brings longevity‑prediction markets pitch to $18T Paris summitQuiver Quantitative · March 25, 2026Enlivex Ltd. Reports $1.23 Billion Net Income for 2025 Driven by Treasury Asset Appreciation | ENLV Stock NewsClinical Trials Arena · November 25, 2025Enlivex’s allogeneic cell therapy benefit continues at six months Mt Newswire · July 13, 2026Enlivex's Allocetra Receives FDA RMAT Designation for Knee Osteoarthritis Benzinga · June 22, 2026Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B Mt Newswire · June 15, 2026Enlivex Therapeutics Granted Patent in Australia for Allocetra to Treat Osteoarthritis Benzinga · June 15, 2026Enlivex Receives Australian Patent Entitled 'Therapeutic Apoptotic Cells For Treatment Of Osteoarthritis' Benzinga · June 1, 2026Enlivex To Feature Extended 3-Month And 6-Months Clinical Data In Knee Osteoarthritis Phase Iia Trial At EULAR European Congress Of Rheumatology Mt Newswire · May 18, 2026Enlivex Doses First US Patient in Phase 2b Knee Osteoarthritis Trial Benzinga · May 18, 2026EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee Osteoarthritis Benzinga · April 21, 2026Enlivex Files Prospectus Related To Resale Of Up To 23.33M Shares By Selling Shareholder